Oral Azacitidine Wins FDA Recognition of AML

Oral Azacitidine Wins FDA Recognition of AML

WASHINGTON — The FDA current an oral formula of azacitidine (Onureg) for continued therapy of adults with acute myeloid leukemia (AML) in first remission nevertheless unable to continue intensive therapy. Supporting knowledge for the approval came primarily from the pivotal…